English

    Overview

  • Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.

  • Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies. 

  • Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.

  • In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.

    • Field of Expertise

  • Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
  • Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
  • Head and Neck Cancers
  • Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
  • Breast cancer
  • Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
  • Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
  • Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
  • Myeloma, Lymphomas, Leukemias
  • Bone and Soft Tissue Tumors (Sarcomas)
  • And other rare or less common solid tumors (Melanoma, Skin Cancers)
  • Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
  • Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
  • Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
  • Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
  • Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
  • Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.

    • Fellowship & Membership

  • European Society of Medical Oncology
  • American Society of Medical Oncology
  • Indian Society of Medical and Pediatric Oncology

    • Languages Spoken

  • English
  • Hindi

    • Awards & Achievements

  • Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
  • Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.

    • Talks & Publications

  • Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
  • An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
  • An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
  • Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
  • Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
  • Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
  • Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
  • Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
  • A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
  • VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
  • Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
  • M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075

    Fellowship & Membership

  • European Society of Medical Oncology
  • American Society of Medical Oncology
  • Indian Society of Medical and Pediatric Oncology

    • Overview

  • Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.

  • Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies. 

  • Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.

  • In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.

    • Field of Expertise

  • Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
  • Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
  • Head and Neck Cancers
  • Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
  • Breast cancer
  • Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
  • Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
  • Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
  • Myeloma, Lymphomas, Leukemias
  • Bone and Soft Tissue Tumors (Sarcomas)
  • And other rare or less common solid tumors (Melanoma, Skin Cancers)
  • Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
  • Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
  • Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
  • Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
  • Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
  • Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.

    • Languages Spoken

  • English
  • Hindi

    • Awards & Achievements

  • Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
  • Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.

    • Talks & Publications

  • Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
  • An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
  • An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
  • Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
  • Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
  • Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
  • Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
  • Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
  • A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
  • VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
  • Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
  • M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075

    Languages Spoken

  • English
  • Hindi

    • Overview

  • Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.

  • Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies. 

  • Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.

  • In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.

    • Fellowship & Membership

  • European Society of Medical Oncology
  • American Society of Medical Oncology
  • Indian Society of Medical and Pediatric Oncology

    • Field of Expertise

  • Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
  • Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
  • Head and Neck Cancers
  • Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
  • Breast cancer
  • Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
  • Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
  • Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
  • Myeloma, Lymphomas, Leukemias
  • Bone and Soft Tissue Tumors (Sarcomas)
  • And other rare or less common solid tumors (Melanoma, Skin Cancers)
  • Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
  • Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
  • Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
  • Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
  • Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
  • Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.

    • Awards & Achievements

  • Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
  • Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.

    • Talks & Publications

  • Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
  • An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
  • An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
  • Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
  • Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
  • Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
  • Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
  • Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
  • A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
  • VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
  • Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
  • M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075

    Field of Expertise

  • Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
  • Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
  • Head and Neck Cancers
  • Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
  • Breast cancer
  • Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
  • Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
  • Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
  • Myeloma, Lymphomas, Leukemias
  • Bone and Soft Tissue Tumors (Sarcomas)
  • And other rare or less common solid tumors (Melanoma, Skin Cancers)
  • Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
  • Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
  • Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
  • Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
  • Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
  • Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.

    • Fellowship & Membership

  • European Society of Medical Oncology
  • American Society of Medical Oncology
  • Indian Society of Medical and Pediatric Oncology

    • Languages Spoken

  • English
  • Hindi

    • Awards & Achievements

  • Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
  • Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.

    • Talks & Publications

  • Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
  • An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
  • An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
  • Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
  • Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
  • Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
  • Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
  • Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
  • A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
  • VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
  • Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
  • M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075

    • Overview

  • Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.

  • Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies. 

  • Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.

  • In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.

    Awards & Achievements

  • Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
  • Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.

    • Fellowship & Membership

  • European Society of Medical Oncology
  • American Society of Medical Oncology
  • Indian Society of Medical and Pediatric Oncology

    • Field of Expertise

  • Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
  • Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
  • Head and Neck Cancers
  • Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
  • Breast cancer
  • Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
  • Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
  • Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
  • Myeloma, Lymphomas, Leukemias
  • Bone and Soft Tissue Tumors (Sarcomas)
  • And other rare or less common solid tumors (Melanoma, Skin Cancers)
  • Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
  • Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
  • Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
  • Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
  • Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
  • Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.

    • Languages Spoken

  • English
  • Hindi

    • Talks & Publications

  • Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
  • An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
  • An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
  • Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
  • Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
  • Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
  • Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
  • Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
  • A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
  • VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
  • Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
  • M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075

    • Overview

  • Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.

  • Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies. 

  • Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.

  • In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.

    Talks & Publications

  • Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
  • An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
  • An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
  • Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
  • Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
  • Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
  • Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
  • Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
  • A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
  • VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
  • Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
  • M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075

    • Overview

  • Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.

  • Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies. 

  • Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.

  • In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.

    • Fellowship & Membership

  • European Society of Medical Oncology
  • American Society of Medical Oncology
  • Indian Society of Medical and Pediatric Oncology

    • Field of Expertise

  • Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
  • Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
  • Head and Neck Cancers
  • Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
  • Breast cancer
  • Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
  • Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
  • Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
  • Myeloma, Lymphomas, Leukemias
  • Bone and Soft Tissue Tumors (Sarcomas)
  • And other rare or less common solid tumors (Melanoma, Skin Cancers)
  • Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
  • Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
  • Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
  • Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
  • Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
  • Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.

    • Languages Spoken

  • English
  • Hindi

    • Awards & Achievements

  • Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
  • Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.

Doctor Videos

Blogs

FAQ's

Patients often seek Dr. Mridul Malhotra’s expertise as the Consultant - Medical Oncology at Manipal Hospitals Dwarka - Delhi. Consult with Dr. Mridul Malhotra, a leading Cancer Specialist in Delhi, for expert diagnosis and personalized treatment plans. Schedule your appointment today for advanced cancer care.

Home Delhi Doctors Dr-mridul-malhotra-oncologist

Appointment
Health Check
Home Care
Contact Us
review icon
Review Us
Call Us